Aridis Pharmaceuticals Inc. Common Stock
ARDS
ARDS was delisted on the 18th of July, 2023.
8 hedge funds and large institutions have $1.21M invested in Aridis Pharmaceuticals Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
71% more capital invested
Capital invested by funds: $711K → $1.21M (+$502K)
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$510K |
| 2 |
BlackRock
New York
|
+$20.7K |
| 3 |
Millennium Management
New York
|
+$864 |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$809 |
| 5 |
JP Morgan Chase
New York
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$5.33K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$42 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $1.04M | +$510K | +73,122 | +98% |
|
|
2
BlackRock
New York
| $160K | +$20.7K | +2,972 | +15% |
|
|
3
UBS Group
Zurich,
Switzerland
| $4K | -$5.33K | -764 | -57% |
|
|
4
Wells Fargo
San Francisco,
California
| $2K | -$42 | -6 | -2% |
|
|
FP
5
Financial Perspectives
Minneapolis,
Minnesota
| $1.77K | – | – | – |
|
|
6
Federated Hermes
Pittsburgh,
Pennsylvania
| $1K | +$809 | +116 | New |
|
|
7
Millennium Management
New York
| $80 | +$864 | +124 | +1% |
|
|
8
JP Morgan Chase
New York
| – | +$7 | +1 | +33% |
|
ARDS Hedge Fund Activity: Q3 2020 in Review
8 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q3 2020, worth a combined $1.21M — up 71% from $711K a quarter earlier.
Fund positioning in ARDS was balanced in Q3 2020: 1 fund opened new positions, 1 closed out, 4 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $510K. The largest seller was UBS Group, cutting an estimated $5.33K.
- 8 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $1.21M of Aridis Pharmaceuticals Inc. Common Stock stock for Q3 2020, up 71% quarter-over-quarter.
- 1 fund opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q3 2020 and 1 closed out, a net change of 0 holders.
- The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q3 2020 was Vanguard Group, an estimated $510K added.
- The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q3 2020 was UBS Group, an estimated $5.33K sold.
Based on aggregated 13F filings for Q3 2020.